Working… Menu

SBRT Pre-operatively for Pancreatic Cancer (SPARC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02308722
Recruitment Status : Unknown
Verified April 2017 by University of Oxford.
Recruitment status was:  Active, not recruiting
First Posted : December 4, 2014
Last Update Posted : May 2, 2018
Oncology Clinical Trials Office
Centre for Statistics in Medicine
CRUK/MRC Oxford Institute for Radiation Oncology
University of Leeds
Information provided by (Responsible Party):
University of Oxford

Brief Summary:
In this study the investigators are testing if the addition of Stereotactic Body Radiation therapy (SBRT) prior to surgery improves surgical outcome in patients with borderline resectable or resectable pancreatic cancer (BRPC).

Condition or disease Intervention/treatment Phase
Pancreatic Neoplasms Radiation: 5-fraction stereotactic body radiation therapy Phase 1

Detailed Description:

This is a single arm prospective phase I dose escalation radiation study investigating 5-fraction stereotactic radiotherapy prior to planned surgical resection in borderline resectable or resectable pancreatic cancer.

Surgical resection is the only potentially curative technique for managing pancreatic cancer. However more than 80% of patients present with disease that cannot be cured with surgical resection. Negative margin (R0 resection), tumour size, absence of lymph nodes metastases are the strongest prognostic indicators for long term survival.

Stereotactic body radiation therapy (SBRT) is a radiation technique for pancreatic cancer where an ablative dose of radiotherapy (RT) can be delivered to a small volume targeting the at risk surgical margin in a short time (1 week versus 5-6 weeks for standard radiotherapy), achieving much higher biologically equivalent dose (BED) (100Gy versus 50Gy) than conventionally fractionated radical RT. The short time of delivery and minimal acute toxicity makes this an attractive treatment option in BPRC as offers the opportunity to integrate systemic treatment. With standard fractionation schedules larger volumes of normal tissue are usually irradiated than with SBRT and an effective dose is limited by toxicity despite the use of Intensity Modulated RT.

This study builds on the current evidence base in SBRT pancreas, which has so far been largely used in the locally advanced setting with promising results and aims to take it a step further. This study aims to test the safety and benefit of pre-operative SBRT, delivering very high local doses to the at risk surgical margin which is usually around the main vessels in the retroperitoneum. The concept of margin-intensive therapy is novel, and aims to deliver a higher radiation dose while limiting toxicity to organs at risk.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Trial of Pre-operative, Margin Intensive, Stereotactic Body Radiation Therapy for Pancreatic Cancer
Study Start Date : April 2015
Actual Primary Completion Date : May 2017
Estimated Study Completion Date : February 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 5-fraction stereotactic body radiation therapy
See intervention
Radiation: 5-fraction stereotactic body radiation therapy

The investigators expect to need a maximum of 3 dose levels investigating dose to the area at risk of involved resection lines and to the tumour bed to assess the tolerability of SBRT in this setting.

Patient entry will commence at level 1. There is the option to de-escalate to Level -1 should 2 or more DLTs be observed at the starting level. SBRT will not be escalated above level 3.

Level -1:

Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 8Gy/# (total dose 40Gy)

Level 1:

Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 9Gy/# (total dose 45Gy)

Level 2:

Tumour (PTV) 6.5Gy/# (total dose 32.5Gy). Area at risk of R1 (PTV_R) 9.5Gy/# (total dose 47.5Gy)

Level 3:

Tumour (PTV) 7Gy/# (total dose 35Gy). Area at risk of R1 (PTV_R) 10Gy/# (total dose 50Gy)

Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) [ Time Frame: 30 days from SBRT day 1 ]
    The maximum tolerated dose (MTD) is defined as the highest dose of margin-intensive SBRT delivered pre-operatively at which no more than 1 of 6 patients or 0 of 3 patients experiences a dose limiting toxicity (DLT)

Secondary Outcome Measures :
  1. Definitive resection rate [ Time Frame: Surgery ]
  2. R0/R1/R2 resection margin rates [ Time Frame: Pathological specimen evaluated at surgery ]
  3. Rate of pathological complete response [ Time Frame: Pathological specimen evaluation post operation ]
  4. Any Late GI AE/other AE > grade 2 CTCAE v4.03 [ Time Frame: >1 month to 6 months post-surgery ]
  5. Overall survival and progression free survival at 12 and 24 months post D1 SBRT [ Time Frame: 12 and 24m FU ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Borderline resectable localised tumour of the pancreatic head/uncinate process/body as per NCCN Guidelines (tumours of the tail of pancreas are not eligible for inclusion) or operable tumour in contact with vein (SMV or PV) not causing distortion or narrowing as defined by CT +/- MRI +/- PET criteria within 28+/- 7 days prior to trial entry de novo or following chemotherapy.
  2. Histologically proven pancreatic ductal adenocarcinoma or cytological proven pancreatic malignancy.
  3. Able to undergo biliary drainage using a stent.
  4. Deemed fit and suitable for surgical resection.
  5. No overt metastases or uncertain status with investigations suspicious of possible metastatic disease (e.g. small equivocal pulmonary nodule(s)).
  6. Male or female, Age >= 16 years.
  7. Life expectancy of at least 6 months.
  8. ECOG performance status 0- 1
  9. The patient is willing and able to comply with the protocol for the duration of the study, and scheduled follow-up visits and examinations.
  10. Written (signed and dated) informed consent and be capable of co-operating with protocol.
  11. Haematological and biochemical indices within defined ranges.

Exclusion Criteria:

  1. Distant metastatic disease or local disease that cannot be encompassed in the SBRT field.
  2. History of previous or concurrent malignancy diagnoses for which the expected prognosis is likely to be worse than that for the current diagnosis of pancreatic cancer (excludes for example: e.g. localised prostate cancer, early colorectal cancer, early breast cancer, curatively-treated basal cell carcinoma of skin, carcinoma in situ of cervix; curatively treated cancer of other sites who are recurrence free for >3 years).
  3. Serious medical or psychological condition precluding trial intervention.
  4. Previous upper abdominal or right chest wall radiotherapy where 30% of the liver has received >15Gy.
  5. PPregnancy. Pregnant or breast-feeding women are ineligible. Women of childbearing potential must use effective methods of contraception.
  6. Any other psychological, social or medical condition, physical examination finding or laboratory abnormality that the Investigator considers makes the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of the trial results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02308722

Layout table for location information
United Kingdom
The Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
St James' Hospital
Leeds, United Kingdom
Northern Centre for Cancer Care, The Freeman Hospital
Newcastle, United Kingdom
City Hospital
Nottingham, United Kingdom
The Churchill Hospital, Oxford University Hospitals Trust
Oxford, United Kingdom
Sponsors and Collaborators
University of Oxford
Oncology Clinical Trials Office
Centre for Statistics in Medicine
CRUK/MRC Oxford Institute for Radiation Oncology
University of Leeds
Layout table for investigator information
Principal Investigator: Prof. Maria A Hawkins, MD FRCR MRCP University of Oxford

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Oxford Identifier: NCT02308722     History of Changes
Other Study ID Numbers: OCTO_054
18496 ( Other Identifier: UKCRN ID )
14138956 ( Registry Identifier: ISRCTN )
First Posted: December 4, 2014    Key Record Dates
Last Update Posted: May 2, 2018
Last Verified: April 2017
Keywords provided by University of Oxford:
Borderline resectable
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases